ArticleJHEP reports : innovation in hepatology2022
Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis.
Article in JHEP reports : innovation in hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- [Interpretation of key updates of the 2026 version of the APASL clinical practice guidelines for the management of chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Guideline
- APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update.Hepatology international · 2026Guideline
- [APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Machine Learning Predicts Hepatocellular Carcinoma Risk from Routine Clinical Data: A Large Population-Based Multicentric Study.Cancer discovery · 2026Article
- Development and validation of machine learning models for diagnosing hepatocellular carcinoma risk and survival in patients with diabetic cirrhosis.Scientific reports · 2026Article
- CDC25C downregulation suppresses HCC growth via mitochondrial stress-induced autophagy and apoptosis.Scientific reports · 2026Article
- Impact of greenhouse gases and air pollutants on the incidence and mortality of HBV and HCV in China.Frontiers in public health · 2026Article
- Impact of H1 Antihistamines on Bacillus Calmette-Guérin-treated Non-muscle-invasive Bladder Cancer.European urology open science · 2026Article
- Validation of a data-driven clustering model for MASLD: Evidence from three large-scale Asian cohorts.JHEP reports : innovation in hepatology · 2026Article
- Explainable artificial intelligence and ensemble learning for hepatocellular carcinoma classification: State of the art, performance, and clinical implications.World journal of hepatology · 2025Review
- Minimal clinical predictors enable machine learning detection of hepatocellular carcinoma in a Filipino cohort.Scientific reports · 2025Article
- Machine Learning-Based Prediction of Decompensation in Hepatitis B Virus-Related Cirrhosis.Diagnostics (Basel, Switzerland) · 2025Article
- Big Data Analytics in Large Cohorts: Opportunities and Challenges for Research in Hepatology.Seminars in liver disease · 2025Review
- Novel blood signature for hepatocellular carcinoma screening.ESMO gastrointestinal oncology · 2025Article
- Article
- Impaired fasting glucose and sulfonylureas increased the risk of major cardiovascular events in patients with inflammatory arthritis.Diabetology & metabolic syndrome · 2025Article
- Advancements in the diagnosis of biliopancreatic diseases: A comparative review and study on future insights.World journal of gastrointestinal endoscopy · 2025Review
- Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA.Alimentary pharmacology & therapeutics · 2025Article
- Machine Learning Approach and Bioinformatics Analysis Discovered Key Genomic Signatures for Hepatitis B Virus-Associated Hepatocyte Remodeling and Hepatocellular Carcinoma.Cancer informatics · 2025Review
- Current and new strategies for hepatocellular carcinoma surveillance.Gastroenterology report · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsAccurate hepatocellular carcinoma (HCC) risk prediction facilitates appropriate surveillance strategy and reduces cancer mortality. We aimed to derive and validate novel machine learning models to predict HCC in a territory-wide cohort of patients with chronic viral hepatitis (CVH) using data from the Hospital Authority Data Collaboration Lab (HADCL).
methodsThis was a territory-wide, retrospective, observational, cohort study of patients with CVH in Hong Kong in 2000-2018 identified from HADCL based on viral markers, diagnosis codes, and antiviral treatment for chronic hepatitis B and/or C. The cohort was randomly split into training and validation cohorts in a 7:3 ratio. Five popular machine learning methods, namely, logistic regression, ridge regression, AdaBoost, decision tree, and random forest, were performed and compared to find the best prediction model.
resultsA total of 124,006 patients with CVH with complete data were included to build the models. In the training cohort (n = 86,804; 6,821 HCC), ridge regression (area under the receiver operating characteristic curve [AUROC] 0.842), decision tree (0.952), and random forest (0.992) performed the best. In the validation cohort (n = 37,202; 2,875 HCC), ridge regression (AUROC 0.844) and random forest (0.837) maintained their accuracy, which was significantly higher than those of HCC risk scores: CU-HCC (0.672), GAG-HCC (0.745), REACH-B (0.671), PAGE-B (0.748), and REAL-B (0.712) scores. The low cut-off (0.07) of HCC ridge score (HCC-RS) achieved 90.0% sensitivity and 98.6% negative predictive value (NPV) in the validation cohort. The high cut-off (0.15) of HCC-RS achieved high specificity (90.0%) and NPV (95.6%); 31.1% of patients remained indeterminate.
conclusionsHCC-RS from the ridge regression machine learning model accurately predicted HCC in patients with CVH. These machine learning models may be developed as built-in functional keys or calculators in electronic health systems to reduce cancer mortality. LAY SUMMARY: Novel machine learning models generated accurate risk scores for hepatocellular carcinoma (HCC) in patients with chronic viral hepatitis. HCC ridge score was consistently more accurate than existing HCC risk scores. These models may be incorporated into electronic medical health systems to develop appropriate cancer surveillance strategies and reduce cancer death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.